Fermion Oy Fermion Oy

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eli Lilly's REYVOW\u2122 (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eli Lilly Japan, Daiichi Sankyo Ink Pact to Commercialise Migraine Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Eli Lilly's Migraine Medication Rayvow","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akums Launches Lasmiditan Tablet to Alleviate Symptoms Associated with Migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly's REYVOW\u2122 (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"REYVOW\u00ae (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHLW Approves Lilly\u2019s Migrane Drug Reyvow, Amgen\u2019s KRAS Inhibitor and More","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ildong\u2019s Migraine Drug Patent Blocks Latecomer\u2019s Market Entry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Lasmiditan Succinate

    Menu

    Lasmiditan Succinate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Akums Lifesciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Akums Launches Lasmiditan Tablet to Alleviate Symptoms Associated with Migraine

              Details:

              Reyvow-Generic (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 05, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ildong Pharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ildong’s Migraine Drug Patent Blocks Latecomer’s Market Entry

              Details:

              Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CHMP Recommends Eli Lilly's Migraine Medication Rayvow

              Details:

              Rayvow will be available as 50 mg, 100 mg and 200 mg film-coated tablets. The active substance of Rayvow is lasmiditan, a 5-hydroxytriptamine 1F (5-HT1F) receptor agonist (ATC code: N02CC), effecting a decrease of neuropeptide release and an inhibition of pain pathways.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MHLW Approves Lilly’s Migrane Drug Reyvow, Amgen’s KRAS Inhibitor and More

              Details:

              Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eli Lilly Japan, Daiichi Sankyo Ink Pact to Commercialise Migraine Drug

              Details:

              Under the agreement, Eli Lilly Japan will hold authorisation for marketing lasmiditan succinate, similar to the humanized anti-CGRP monoclonal antibody Emgality (galcanezumab), and Daiichi Sankyo will take charge of its distribution and sales after marketing approval.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Daiichi Sankyo

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              REYVOW® (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study

              Details:

              Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eli Lilly's REYVOW™ (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study

              Details:

              Adults who took REYVOW C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo, according to results from the recently completed Phase 3 study CENTURION.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eli Lilly

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly's REYVOW™ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription

              Details:

              Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

              Lead Product(s): Lasmiditan

              Therapeutic Area: Neurology Product Name: Reyvow

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Metrochem Lasmiditan
              Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.
              Close
              4
              Post Enquiry
              POST ENQUIRY